A Phase 4 interventional study of nph insulin and human insulin in Insulin-requiring Type 2 Diabetes Mellitus, sponsored by ikfe-CRO GmbH. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-29.
Sponsored by ikfe-CRO GmbH · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 29th largest by planned enrollment, is one of 3 that started in 2011, is one of 7 in phase 4, and was the 36th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
ikfe-CRO GmbH is the lead sponsor of 8 studies on the registry; none are open to participants now.
ikfe-CRO GmbH has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.
To compare fasting intact proinsulin secretion at the beginning and after a 24 week treatment period.
after 24 weeks of treatment.
To investigate the changes of
between visit 2 (baseline), visit 6 (12 weeks) and visit 8 (final visit after 24 weeks).
To investigate the number of patients with normal values for parameters hsCRP, adiponectin, and intact proinsulin after 24 weeks of treatment (responder rates).
-Primary efficacy variable: Fasting intact proinsulin concentration at timepoint Visit 2 (Baseline) and Visit 8 (after 24 week treatment)
-Secondary efficacy variables: All secondary parameters will be assessed after 24 weeks of treatment and compared versus baseline assessment.
Additionally the following parameters will be assessed at visit 6 and will be compared with visit 2 and visit 8:
Medication/Dosage:
Insulin glargine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)NPH Insulin, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Insulin glulisine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Human Insulin, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)
-Study Duration: Duration of study participation for one patient is approximately 26 weeks. Overall total duration of the study is approximately 10 months.
Design:
This is a randomized in four arms, open-label, multi-center study. Population Patients with Type 2 Diabetes mellitus, Sample Size n = 60 (15 per arm)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
Drug: nph insulin · Drug: Insulin glulisine
Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
Drug: human insulin
Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
Drug: Insulin Glargine · Drug: Insulin glulisine
Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
Drug: human insulin · Drug: Insulin Glargine
Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Also known as: Insuman Basal
Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL. human insulin: bolus injections before each main meal
Also known as: Insuman Rapid
Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Also known as: Lantus
Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL. Insulin glulisine: bolus injections before each main meal
Also known as: Apidra
Fasting Intact Proinsulin
The difference of fasting intact proinsulin after 24 weeks of treatment compared to baseline.
Time frame: Change from baseline at 24 weeks
Weight
To evaluate the changes of weight after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
hsCRP
To evaluate changes of hsCRP after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
Adiponectin
To evaluate changes of adiponectin after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
MMP-9
To evaluate changes of MMP-9 after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks
To evaluate changes of OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes) after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
HOMA-IR score
To evaluate changes of HOMA-IR score after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
HbA1c
To evaluate changes of HbA1C after 24 weeks of treatment compared to baseline.
Time frame: Baseline and after 24 weeks of treatment.
Weight
To evaluate changes of weight after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
hsCRP
To evaluate changes of hsCRP after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
Adiponectin
To evaluate changes of adiponectin after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
Fasting intact Proinsulin
To evaluate changes of fasting intact proinsulin after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
Glucose
To evaluate changes of Glucose after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
HbA1c
To evaluate changes of HbA1c after 12 weeks of treatment compared to baseline and compared to 24 weeks.
Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.
Responder rate
To investigate the number of patients with normal values for parameters hsCRP, adiponectin, and intact proinsulin after 24 weeks of treatment (responder rates).
Time frame: After 24 weeks of treatment compared to baseline.
Hypoglycemic events.
Hypoglycemic events defined as blood glucose below 63 mg/dl.
Time frame: Baseline up to 24 weeks.
The record gives a start of Oct 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin, Regular, Human · Insulin Glargine · Insulin glulisine
ikfe-CRO GmbH